M
Martin E. Fernandez-Zapico
Researcher at Mayo Clinic
Publications - 231
Citations - 14148
Martin E. Fernandez-Zapico is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Pancreatic cancer & Transcription factor. The author has an hindex of 47, co-authored 205 publications receiving 12174 citations. Previous affiliations of Martin E. Fernandez-Zapico include University of Saint Mary & McGill University.
Papers
More filters
Posted ContentDOI
p97/VCP induces GLI1 to control XBP1-dependent endoplasmic reticulum stress transcriptional response
Kim Barroso,Luciana L. Almada,R. Olson,H. Auner,R. Pedeux,Juan L. Iovanna,Eric Chevet,Martin E. Fernandez-Zapico +7 more
TL;DR: This work demonstrates that p97/VCP orchestrates the activation of GLI1 upon ER stress in a Hh ligand-independent fashion and defines the interplay between the newly identified p97 /VCP-mSin3A-HDAC1/2 complex and the transcription factor USF2 as an essential player in this process.
Posted ContentDOI
“Tumor Explants Elucidate a Cascade of Paracrine SHH, WNT, and VEGF Signals Driving Pancreatic Cancer Angiosuppression”
Marie C. Hasselluhn,Amanda R. Decker-Farrell,Lukas Vlahos,Dafydd H. Thomas,Álvaro Curiel-García,H. Carlo Maurer,Urszula Waśko,Lorenzo Tomassoni,Stephen A. Sastra,Carmine F. Palermo,Tanner Dalton,Alice Ma,Fang-fang Li,Ezequiel J. Tolosa,Hanina Hibshoosh,Martin E. Fernandez-Zapico,Alex Muir,Andrea Califano,Kenneth P. Olive +18 more
TL;DR: In this paper , the authors identify a cascade of paracrine signals between multiple cell types that act sequentially to suppress angiogenesis in PDAC, leading to inhibition of WNT signaling in fibroblasts and epithelial cells.
Journal ArticleDOI
mTOR-Dependent ARID1A Degradation: A New Twist in the Genetic-Epigenetic Interplay Driving Hepatocellular Carcinoma.
TL;DR: Zhang et al. as mentioned in this paper revealed a role for oncogenic mTOR signaling leading to the degradation of a prominent chromatin remodeler, ARID1a, establishing an altered, protumor chromatin landscape in hepatocellular carcinoma (HCC) controlling tumor deve-lopment and treatment resistance.
Journal ArticleDOI
It Takes a Village to Overcome KRAS Dependence in Pancreatic Cancer
TL;DR: Through extensive experimentation both in vitro and in vivo, the authors reveal that the HDAC5-CCL2 axis drives the recruitment of tumor-associated macrophages to the TME to provide trophic signaling.
Journal ArticleDOI
CLO23-030: MC200402-Single-Arm Phase 2 Study of the FGFR Inhibitor Futibatinib (Futi) in Combination With Pembrolizumab (Pem) in Patients With FGF19 Expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC)
Nguyen H. Tran,Joseph J. Larson,Fang Shu Ou,Amit Mahipal,Shaylene A. McCue,Rondell P. Graham,Martin E. Fernandez-Zapico,Alexander Revzin,Lionel A. Kankeu Fonkoua,Lynn M. Flickinger,Sean P. Cleary,Tanios Bekaii-Saab,Mitesh J. Borad,Robert R. McWilliams,Aminah Jatoi,Wen Wee Ma +15 more
TL;DR: In this paper , the FGFR inhibitor Futibatinib (Futi) was used in combination with Pembrolizumab (Pem) in patients with FGF19 expressing Advanced or Metastatic Hepatocellular Carcinoma (aHCC).